Fate Therapeutics, Inc. vs Merck & Company, Inc. — Stock Comparison

FATE
Fate Therapeutics, Inc.
$1.53
▲ 22.40%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.4/10

Q·Score Breakdown

5.4
Bearish
Overall
6.7
Neutral
1.6
Quality
6.2
9.7
Health
7
4.7
Growth
6.2
6.5
Valuation
7.2
5.2
Sentiment
7.1
FATE

Clean balance sheet with low leverage (0.4× debt-to-equity).

low return on equity (-52%).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

HOLD
Target $5.19 (+239.1%)
8 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

FATE
MRK
Trailing P/E
31.5×
-1.5×
Forward P/E
11.5×
0.0%
Profit Margin
13.6%
0.0%
Gross Margin
76.6%
-51.8%
ROE
-26.4%
Revenue Growth
4.9%
Earnings Growth
2.24
Beta
0.28
Price / Book
$178M
Market Cap
$277.0B
$1 – $2
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →